Functional and molecular characterization of mouse Gata2-independent hematopoietic progenitors.

Blood
Polynikis KaimakisElaine Dzierzak

Abstract

The Gata2 transcription factor is a pivotal regulator of hematopoietic cell development and maintenance, highlighted by the fact that Gata2 haploinsufficiency has been identified as the cause of some familial cases of acute myelogenous leukemia/myelodysplastic syndrome and in MonoMac syndrome. Genetic deletion in mice has shown that Gata2 is pivotal to the embryonic generation of hematopoietic stem cells (HSCs) and hematopoietic progenitor cells (HPCs). It functions in the embryo during endothelial cell to hematopoietic cell transition to affect hematopoietic cluster, HPC, and HSC formation. Gata2 conditional deletion and overexpression studies show the importance of Gata2 levels in hematopoiesis, during all developmental stages. Although previous studies of cell populations phenotypically enriched in HPCs and HSCs show expression of Gata2, there has been no direct study of Gata2 expressing cells during normal hematopoiesis. In this study, we generate a Gata2Venus reporter mouse model with unperturbed Gata2 expression to examine the hematopoietic function and transcriptome of Gata2 expressing and nonexpressing cells. We show that all the HSCs are Gata2 expressing. However, not all HPCs in the aorta, vitelline and umbilical arte...Continue Reading

References

Jan 1, 1994·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·S M Hsu, P L Hsu
Aug 18, 1997·Biochemical and Biophysical Research Communications·K Sakai, J i Miyazaki
Aug 10, 2001·Experimental Hematology·J Palis, M C Yoder
Oct 7, 2004·The Journal of Experimental Medicine·Kam-Wing LingElaine Dzierzak
Jan 20, 2005·The Journal of Experimental Medicine·Stephen L NuttLi Wu
Mar 2, 2005·Developmental Cell·Christos GekasHanna K A Mikkola
Mar 9, 2005·Proceedings of the National Academy of Sciences of the United States of America·Xinmin ZhangMarc Montminy
Sep 6, 2005·Experimental Hematology·Thierry JaffredoMarella de Bruijn
Oct 4, 2005·Proceedings of the National Academy of Sciences of the United States of America·Aravind SubramanianJill P Mesirov
Mar 31, 2007·Development·Melin KhandekarJames Douglas Engel
Oct 27, 2007·Proceedings of the National Academy of Sciences of the United States of America·John E PimandaBerthold Göttgens
Mar 12, 2009·Methods in Molecular Biology·Katrin Ottersbach, Elaine Dzierzak
Mar 20, 2009·PLoS Biology·Amit J SabnisBenjamin S Braun
Mar 20, 2009·Development·Tessa PeterkinRoger Patient
Jun 15, 2011·Blood·Natalija Buza-VidasSten Eirik Waelgaard Jacobsen
Jan 24, 2012·Blood·Chia-Jui KuJames Douglas Engel
Sep 22, 2012·The Journal of Clinical Investigation·Kirby D JohnsonEmery H Bresnick
Sep 22, 2012·The Journal of Clinical Investigation·Kim-Chew LimJames Douglas Engel
Dec 12, 2012·Nature Biotechnology·Cole TrapnellLior Pachter
Jan 22, 2013·Nature Neuroscience·Katrin KierdorfMarco Prinz
Mar 7, 2013·Nature Communications·Haruko NakanoAtsushi Nakano
Aug 27, 2013·Nature Immunology·Catherine FrelinNorman N Iscove

❮ Previous
Next ❯

Citations

Aug 21, 2016·FEBS Letters·Mari-Liis KautsElaine Dzierzak
Dec 9, 2017·The Journal of Experimental Medicine·Christina EichElaine Dzierzak
Jun 20, 2019·Leukemia & Lymphoma·Saeid ShahrabiNajmaldin Saki
Mar 20, 2018·Histochemistry and Cell Biology·Ewa Jankowska-SteiferAnna Ratajska
Oct 24, 2018·Development·Mathieu TremblayMaxime Bouchard
Oct 10, 2020·Annual Review of Physiology·Yinyu Wu, Karen K Hirschi
Dec 26, 2017·Current Opinion in Cell Biology·Martin Etzrodt, Timm Schroeder

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Cell Fate Conversion By mRNA

mRNA-based technology is being studied as a potential technology that could be used to reprogram cell fate. This technique provides the potential to generate safe reprogrammed cells that can be used for clinical applications. Here is the latest research on cell fate conversion by mRNA.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.